Monophosphoryl lipid a (MPL) as an adjuvant for anti-cancer vaccines: Clinical results

Advances in Experimental Medicine and Biology

Volumn 667, Issue , 2009, Pages 111-123

  Cluff, Christopher W ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; ADJUVANT; CANCER VACCINE; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 1ALPHA; JBT 1001; LIPID A DERIVATIVE; MAGE3 VACCINE; MELACINE; MELANOMA ANTIGEN 3; MUC 1 VACCINE; ONCOVAX CLB; PHOSPHORYL LIPID A; PLACEBO; PROSTATE SPECIFIC ANTIGEN; QS 21; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; STIMUVAX; TAMOXIFEN; THERATOPE; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOREACTIVITY; INJECTION SITE PRURITUS; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; RIGOR; SINGLE DRUG DOSE;

ADJUVANTS, IMMUNOLOGIC; CANCER VACCINES; HUMANS; LIPID A;

BACTERIA (MICROORGANISMS); HUMAN PAPILLOMAVIRUS TYPE 16; MYCOBACTERIUM; NEGIBACTERIA;

EID: 77952540334     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1603-7_10     Document Type: Article

References (73)

1. Otto F, Schmid P, Mackensen A et al. Phase II trial of intravenous endotoxin in patients with colorecral and nonsmall cell lung cancer. Eur J Cancer 1996; 32:1712-1718. (Pubitemid 26306882)
2. Engelhardt R. Mackensen A. Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 1991; 51:2524-2530.
3. Mackensen A, Galanos C.Engelhardt R. Modulating activity of interferon-gamma on endotoxin-induced cyrokine production in cancer patients. Blood 1991; 78:3254-3258.
4. Mackensen A. Galanos C. Wehr U et al. Endotoxin tolerance : regulation of cytokine production and cellular changes in response to endotox in application in cancer patients. Eur Cytokine Nerw 1992; 3:571-579.
5. Goto S. Sakai S. KeraJ et al. Intradermal administration of lipopolysaccharide in treatment of human cancer. Cancer Immunol Imrnunother 1996; 42(4) :255-261. (Pubitemid 26183208)
6. Vosika GJ. Barr C. Gilbertson D. Phase-I study of intravenous modified lipid A. Cancer Immunol Immunother 1984: 18(2):107-112. (Pubitemid 15213363)
7. Kiani A, Tschiersch A. Gaboriau E et al. Downregulation of the pro inflammatory cyrokine response to endotox in by pretreatment with the nontoxic lipid A analog SDZ MRL 953 in cancer patients. Blood 1997; 90(4) :1673-1683. (Pubitemid 27355442)
8. de Bono JS. Dalgleish AG, CarmichaelJ et al. Phase 1 study of ONO-4007. a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 2000; 6(2) :397-405. (Pubitemid 30111456)
9. Myers KR. Truchot AT, WardJ et al. A critical determinant of lipid A endoroxic activity. In: Nowotny A. Spitzer JJ. Ziegler EJ, editors. Cellular and Molecular Aspects of Endotoxin Reactions. Amsterdam: Elsevier Sciences Publishers B V, 1990:145-156.
10. Ulrich JT, Masihi KN. Lange W. Mechanisms of nonspecific resistance to microbial infections induced by trehalose dimycolate (TDM) and monophosphoryllipid A (MPL). In: Masihi KN. Lange W; editors. Advances in the Bioscicnces, Great Britain: Pergamon Journals Ltd., 1988:167-178.
11. EvansJT. Cluff CW; Johnson DA et al, Enhancement of antigen- specificimmunity via the TLR4ligands MPL adjuvant and Ribi 529. Expert Review Vaccines 2003; 2(2) :219-229.
12. Woodlock TJ. Sahasrabudhe DM. Marquis DM et al. Active specific immunotherapy for metastatic colorectal carcinoma: Phase I study of an allogeneic cell vaccine plus low-dose interleukin-la. J Irnmunother 1999; 22(3) :251-259. (Pubitemid 29226986)
13. Sherye SF, Frodin J-E. Christensson B. Immunohistochemical mon itoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-01A). Cancer Immunol Imrnunorher 1988; 27:154-162.
14. NeidhartJ. Allen KO. Barlow DL et al. Immun ization of colorecral cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryllipid A in liposomal emulsion, with and without granulocyte-macrophage colony-stimulating factor. Vaccine 2004; 22(5-6):773-780. (Pubitemid 38114910)
15. Papsidero LD. Kuriyama M. Wang MC et al. Prostate antigen: A marker for human prostate epithelial cells. J Natl Cancer Insr 1981; 66(1) :37-42. (Pubitemid 11163233)
16. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Uro11991; 145(5):907-923.
17. Harris DT, Matyas GR, Mastrangelo MJ et al. Inducing immunity to prostate specific antigen (PSA) in prostate cancer patients. Proc ASCO 1999; 18:1693.
18. Meidenbauer N, Harris DT, Spitler LE et al. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000; 43(2):88-100. (Pubitemid 30220611)
19. Mitchell MS, Kan-Mitchell J, Kempf RA et al. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988; 48(20):5883-5893.
20. Mitchell MS, Harel W; Kempf RA et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990; 8(5):856-869. (Pubitemid 20148278)
21. Vose BM. Quantitarion of proliferative and cytotoxic precursor cells directed against human tumours: limiting dilution analysis in peripheral blood and at the tumour site. Int J Cancer 1982 ; 30(2):135-142. (Pubitemid 12055832)
22. Mitchell MS, Harel W; Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol1992; 10(7):1158-1164.
23. Sosman JA, Sondak VK. Melacine: An allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2003 ; 2(3) :353-368. (Pubitemid 36713362)
24. Elliott GT, McLeod RA, PerezJ et al. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (rheraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol1993; 9(3) :264-272. (Pubitemid 23154466)
25. Mitchell MS, Von Eschen KB. Phase III trial of Melacine melanoma theraccine versus combination chemotherapy in the treatment of stage IV melanoma. Proceedings of the American Society of Clinical Oncology 1997; 16,494a.
26. Sosman JA, Unger JM, Liu PY et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine : impact of HLA class I antigen expression on outcome, J Clin Oncol 2002; 20(8):2067-2075. (Pubitemid 34408797)
27. Sondak VK, Sosman JA. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine', Semin Cancer Biol 2003; 13:409-415. (Pubitemid 38156132)
28. Sosman JA, Sondak VK. Melacine : An allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines 2003 ; 2(3) :353-368. (Pubitemid 36713362)
29. Mitchell MS, Jakowatz J, Harel W et al. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Onco11994; 12(2):402-411. (Pubitemid 24056416)
30. Vaishampayan U, Abrams J, Darrah D et al. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 2002; 8(12):3696-3701. (Pubitemid 35424758)
31. Mitchell MS. Immunotherapy as part ofcombinations for the treatment of cancer. Inc Immunopharmacol 2003; 3(8):1051-1059. (Pubitemid 36830850)
32. Mitchell MA, Abrams J, Kashani-Saber M et al. Interim analysis of a phase III stratified randomized trial of Melacine + low-dose Intron-A versus high-dose Intron-A for resected stage III melanoma. Am Soc Clin Oncol 2003; 22:709a.
33. Schultz N, Oratz R, Chen D et al. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine 1995 ; 13(5):503-508.
34. Eron 0, Kharkevirch DD, Gianan MA et al. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Cancer Res 1998; 4(3):619-627. (Pubitemid 28193560)
35. Wong R, Lau R, ChangJ et al. Immune responses to a class II helper peptide epitope in patients with stage III /IV resected melanoma. Clin Cancer Res 2004; 10(15):5004-5013. (Pubitemid 39099774)
36. Lienard D, Rimoldi D, Marchand M et al. Ex vivo detectable activation of Melan-Avspecific T'cells correlating with inflammatory skin reactions in melanoma patients vaccinated with pepcldes in IFA. Cancer Immun 2004; 4:4.
37. Marchand M, Punt CJ, Aamdal S et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report. Eur J Cancer 2003; 39(1):70-77. (Pubitemid 36005427)
38. Vantomrne V, Dantinne C, Amrani N. Immunologic analysis of a phase lIII study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3 -positive tumors. J Immunorher 2004; 27:124-135. (Pubitemid 38282732)
39. + T-cell responses to MAGE-3 protein in lung cancer patients. J Immunol 2004 ; 172(5) :3289-3296. (Pubitemid 38263721)
40. Brichard V. Development of cancer vaccines with the MAGE-3 protein. Cancer Immunity 2005; 5(1) :16.
41. Brichard V. CVADD 2005; Portugal.
42. Zotter S, Hageman PC, Lossnitzer A et al. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 1988; 11-12:55-101. (Pubitemid 19206475)
43. Ho SB, Niehans GA, Lyfiogr C et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993 ; 53(3) :641-651. (Pubitemid 23059449)
44. Burchell J, Gendler S, Taylor-Papadimitriou J et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res 1987; 47(20) :5476-5482. (Pubitemid 17152966)
45. Kjeldsen T, Clausen H, Hirohashi S et al. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6alpha-N-acetylgalactosaminyl(sialosyl-Tn) epitope. Cancer Res 1988; 48(8) :2214-2220.
46. Ramanathan RK, Lee KM, McKolanis Jet al. Phase I study of a MUCI vaccine composed of different doses of MUCI peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005; 54(3) :254-264. (Pubitemid 40174243)
47. Palmer M, Parker J, Modi S et al. Phase I study of the BLP25 (MUCl peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV nonsmall-cell lung cancer. Clin Lung Cancer 2001; 3(1):49-57. (Pubitemid 32904315)
48. North SA, Graham K, Bodnar D et al. A pilot study of the liposomal MUC 1 vaccine BLP25 in prostate specific antigen failures atter radical prostatectomy. J Urol 2006; 176(1) :91-95. (Pubitemid 43815368)
49. Butts C, Murray N, Maksymiuk A et al. Randomized phase lIB trial of BLP25 liposome vaccine in stage IIIB and IV nonsmall-celliung cancer. J Clin Onco12005; 23(27):6674-6681. (Pubitemid 46190262)
50. Machiels JP, Reilly RT, Emens LA et al. Cyclophosphamide, doxorubicin and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001; 61(9) :3689-3697. (Pubitemid 32694981)
51. Bass KK, Mastrangelo MJ. Immunoprotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer ImmunolImmunother 1998; 47:1-12. (Pubitemid 28430525)
52. Longenecker BM, MacLean G. Prospects for mucin epitopes in cancer vaccines. Immunologist 1993; 1:89-93.
53. Itzkowitz SH, Bloom EJ, Kokal WA et al. Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorecral cancer patients. Cancer 1990; 66(9) :1960-1966. (Pubitemid 20385969)
54. Springer GF. T and Tn, general carcinoma autoantigens. Science 1984; 224(4654):1198-1206. (Pubitemid 14109457)
55. Kobayashi H, Terao T, Kawashima Y. Serum sialyl Tn as an independent predictor of poor prognos is in patients with epithelial ovarian cancer. J Clin Oncol 1992; 10(1):95-101.
56. Thor A, Ohuchi N, Szpak CA et al. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986; 46(6) :3118-3124. (Pubitemid 16074337)
57. Nuti M, Teramoto YA, Mariani-Costantini Ret al. A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations. Int J Cancer 1982; 29(5) :539-545. (Pubitemid 12114628)
58. Yoneawa S, Tachidawa T, Shin S. Sialosyl-Tn antigen: its distribution in normal human tissues and expression in adenocarcinomas. AmJ Clin Parhol 1992; 98:167-174.
59. Longenecker BM, Reddish M, Miles D et al. Synthetic Tumor-Associated Sialyl-Tn Antigen as an Immunotherapeutic Cancer Vaccine. Vaccine Res 1993; 2(3) :151-162. (Pubitemid 24066078)
60. O'Boyle K, Zamore R, Adluri S et al. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res 1992; 52(20) :5663-5667.
61. Berendt MJ, North RJ. Tvcell-mediared suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980; 151(1) :69-80. (Pubitemid 10168540)
62. MacLean GD, Reddish M, Koganty RR et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Derox adjuvant. Cancer Immunol Imrnunother 1993; 36(4) :215-222. (Pubitemid 23069240)
63. Miles DW; Towlson KE, Graham R et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer 1996; 74(8):1292-1296. (Pubitemid 26360122)
64. MacLean GD, Miles DW; Rubens RD et al. Enhancing the effect of THERATOPE Stn-KLN cancer vaccine in patients with metastatic breast cancer by pretreatment with low dose intravenous cyclophosphamide. J Immunorher 1996; 19(4):309-316. (Pubitemid 26313521)
65. Miles D, Ibrahim N, Roche H. An international randomized phase III clinical trial of STn-KLH (Therarope) therapeutic cancer vaccine in metastic breast cancer patients. Proceedings 27th Annual San Antonio Breast Cancer Symposium 2003;(36).
66. Ibrahim NK, Murray J, ParkerJ. Humoral immune-response to naturally occurring STn in metastatic breast cancer (MBC prs) treated with STn-KLH vaccine. Am Soc Clin Oncol 2004; 22:S174.
67. Majordomo J, Tres A, Miles D. Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in Stave IV breast cancer following front-line chemotherapy. Proc Am Soc Clin Oncol 2004 ; 22:1882S.
68. Holmberg LA. Oparin DV. Gooley T et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy. autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant 2000: 25(12) :1233-1241. (Pubitemid 30428137)
69. Holmberg LA. Sandmaier BM. Theratope(R) vaccine (STn-KLH). Expert Opin Biol Ther 2001 : 1(5):881-891.
70. Holmberg LA. Oparin DV. Gooley T et al. The role of cancer vaccines following autologous stern cell rescue in breast and ovarian cancer patients: experience wirh the STn-KLH vaccine (Therarope). Clin Breast Cancer 2003: 3 SuppI4:S144-S151.
71. Holmberg LA. Sandmaier BM. Vaccination wirh Theratope (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines 2004: 3(6) :655-663. (Pubitemid 39576752)
72. Khleif SN. Abrams SI. Hamilton JM et al. A phase 1 vaccine trial with pepridcs reflecting ras oncogene mutations of solid rumors. J Imrnunother 1999: 22(2):155-165. (Pubitemid 29135900)
73. Johnson AG. Molecular adjuvants and immunomodularors: new approaches to immunization. Clin Microbiol Rev 1994: 7(3):277-289. (Pubitemid 24216121)